Quantcast

Latest cell therapy Stories

2014-08-29 23:10:02

For more than a week, Boston’s Adult Stem Cell Technology Center, LLC has been declining offers from participants in the Amyotrophic Lateral Sclerosis (ALS) Ice Bucket Challenge who wish to make donations for research that does not use human embryonic stem cells or tissues derived from aborted fetuses. The company has informed those wishing to donate that its for-profit status prevents it from inviting or receiving charitable donations. Boston, MA (PRWEB) August 29, 2014 Due to a...

2014-08-27 08:26:50

Dose Escalation Clinical Trial to Test Initial Safety and Activity of AST-OPC1 in Patient Population with the First Indication Targeted for Product Registration MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- Asterias Biotherapeutics Inc. (OTCBB: ASTY) has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury. The approved trial follows the...

2014-08-25 08:27:03

- Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT - MENLO PARK, Calif., Aug. 25, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today that it will host an investor briefing conference call and slide presentation via webcast on Wednesday, August 27, 2014, at 4:30 p.m. EDT, 1:30 p.m. PDT. At this briefing, Asterias management will review the Company's business...

2014-08-22 23:05:03

Cryo-Cell International, Inc., the world’s first cord blood bank, announced today that it has provided funding to complete an Investigational New Drug Application (IND) for a FDA approved Phase I clinical trial for patients that have amyotrophic lateral sclerosis (ALS or Lou Gehrig's) disease using umbilical cord blood cells. Oldsmar, FL (PRWEB) August 22, 2014 This funding was made through an additional investment in Cryo-Cell’s cell therapy research affiliate, Saneron CCEL...

2014-08-21 08:29:07

SAN DIEGO, Aug. 21, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately held regenerative medicine company announced today that it has entered into a Rights Agreement with Janssen Research & Development LLC (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement provides Janssen with a future right to evaluate a transaction related to the VC-01(TM) combination product that ViaCyte is developing for type 1 diabetes. This right will continue...

2014-08-21 08:28:11

- Welcomes New Shareholders Who Received Series A Shares from Geron Corporation - MENLO PARK, Calif., Aug. 21, 2014 /PRNewswire/ -- Asterias Biotherapeutics, Inc. (OTCBB: ASTY), a leading biotechnology company in the emerging field of regenerative medicine, announced today the appointments of Andrew ("Andy") Arno and Natale ("Nat") Ricciardi to the Company's newly expanded Board of Directors. With these additions, the Asterias Board of Directors now comprises eight directors, three...

2014-08-20 08:27:38

Growth Funding to Expand CCB's Presence in Reproductive and Stem Cell Markets LOS ANGELES, Aug. 20, 2014 /PRNewswire/ -- California Cryobank (CCB), a global leader in reproductive tissue donor services and storage and stem cell banking, announced today that it has been acquired by equity investors Longitude Venture Partners II, L.P. ("Longitude") and NovaQuest Pharma Opportunities Fund III, L.P. ("NovaQuest"). Founded in 1977 by Dr. Charles Sims and Dr. Cappy Rothman, California...

2014-08-19 08:30:47

Company Plans to Immediately Initiate Phase 1/2 Clinical Trial SAN DIEGO, Aug. 19, 2014 /PRNewswire/ -- ViaCyte, Inc., a privately-held regenerative medicine company, announced today that the U.S. Food and Drug Administration ("FDA") has accepted the company's Investigational New Drug Application ("IND") for its VC-01(TM) candidate cell replacement therapy to treat type 1 diabetes. The company plans to promptly initiate a Phase 1/2 clinical trial which it believes to be the first...

2014-08-19 04:22:39

JERUSALEM, August 19, 2014 /PRNewswire/ -- Gamida Cell [http://www.gamida-cell.com ], a world leader in stem cell expansion technologies and therapeutic products, announced today that it has signed an investment and option agreement with Novartis Pharma AG [http://www.novartis.com ] ("Novartis"). According to the agreement, Novartis will invest $35 million in Gamida Cell and in return will receive 15% equity and an option to fully acquire Gamida Cell. The option is exercisable...

Specialized Immune Cells Could Stop Cancer Spread
2014-08-18 03:54:50

Walter and Eliza Hall Institute of Medical Research Melbourne researchers have revealed the critical importance of highly specialized immune cells, called natural killer cells, in killing melanoma cells that have spread to the lungs. These natural killer cells could be harnessed to hunt down and kill cancers that have spread in the body. The team, from the Walter and Eliza Hall Institute, also found natural killer cells were critical to the body’s rejection of donor bone marrow...


Word of the Day
maffling
  • To stammer.
  • Present participle of maffle, to stammer.
  • A simpleton.
The word 'maffle' may come from a Dutch word meaning 'to move the jaws' or a French word meaning 'having large cheeks'.